Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.

Hynes, Nancy and Dey, Julien H (2009) PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell, 15 (5). pp. 353-355. ISSN 1878-3686

Abstract

Trastuzumab targets ErbB2 and is used for treating ErbB2-overexpressing breast cancers. In this issue of Cancer Cell, Junttila et al. show that trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K complexes and blocks AKT signaling; if PI3K is mutated, complex disruption does not inhibit AKT, which explains why trastuzumab is ineffective in some tumors.

Item Type: Article
Related URLs:
Additional Information: author can archive post-print (ie final draft post-refereeing); Publisher's version/PDF cannot be used
Related URLs:
Date Deposited: 14 Dec 2009 13:50
Last Modified: 31 Jan 2013 01:00
URI: https://oak.novartis.com/id/eprint/1009

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.